5-Amino-1MQ is often marketed as a “peptide,” but it is a synthetic small-molecule NNMT inhibitor studied mainly in cells and mice. It is not an FDA-approved weight-loss drug, and Chia does not offer it. If your goal is medical weight loss, a licensed clinician can review evidence-based options such as semaglutide or tirzepatide.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy 5-Amino-1MQ for personal use?
You may see 5-Amino-1MQ sold online, often with “research use only” or “not for human consumption” language. That kind of listing is not the same as getting a prescription from a licensed clinician or receiving medication from a state-licensed pharmacy.
The central issue is evidence and oversight. In the main published study, 5-Amino-1MQ was investigated as a selective, membrane-permeable NNMT inhibitor in cell systems and in a diet-induced obesity mouse model—not as an approved patient treatment 1. If you are comparing online listings, our deeper guide to 5-Amino-1MQ explains the evidence gap in more detail.
Why many online listings say “research use only”
“Research use only” usually means the seller is positioning the product for laboratory work, not for use by people. A purity claim or certificate of analysis may describe a chemical lot, but it does not show that the product was reviewed by FDA for safety, effectiveness, manufacturing quality, or patient labeling 6.
Why buying a research chemical is different from getting a prescription
A prescription pathway includes diagnosis, medication history, contraindication screening, side-effect counseling, and follow-up. A research-chemical purchase usually does not include those safeguards, and the buyer may not know whether the product is sterile, accurately labeled, or appropriate for their health history 6.
What to check before taking any compound marketed for weight loss
- Is it FDA-approved for obesity or weight management?
- Is a licensed clinician reviewing your health history, medications, pregnancy status, kidney or liver history, and eating-disorder risk?
- Is the product dispensed by a state-licensed pharmacy when it is a prescription medication?
- Does the label say “not for human consumption” or “research use only”?
- Are you being given realistic risks, side effects, and monitoring—not just a mechanism claim?
What is 5-Amino-1MQ?
5-amino-1-methylquinolinium is a synthetic small molecule, not a peptide chain. It is often discussed in “peptide” circles because people are interested in body composition, NAD+ biology, and metabolic research, but chemically it is different from therapeutic peptides 1.
You may see related names such as 5-amino-1-methylquinolinium iodide or 5-amino-1-methylquinolinium chloride. Those names refer to salt forms of the same core compound used in research chemistry contexts.
Why it is commonly mislabeled as a peptide
Peptides are short chains of amino acids. 5-Amino-1MQ is not built that way; it is a quinolinium small molecule. The confusion likely comes from online “peptide” stores grouping many investigational metabolic compounds together. For a plain-language overview, see our guide to what peptides are used for.
How it differs from therapeutic peptides and GLP-1 medications
GLP-1 medications work through gut-hormone receptor pathways that help regulate appetite, glucose, and gastric emptying. Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist; both active ingredients have large human obesity trials and FDA-approved brand products for chronic weight management 2, 3, 4, 5.
How is 5-Amino-1MQ supposed to work?
NNMT stands for nicotinamide N-methyltransferase. In plain language, it is an enzyme that helps process nicotinamide and uses methyl groups from S-adenosylmethionine, or SAM, in the process 1.
The proposed theory is that inhibiting NNMT may shift adipocyte, or fat-cell, metabolism. In the 2018 study, NNMT inhibition with 5-Amino-1MQ affected NAD+ and SAM-related pathways and reduced lipogenesis markers in cultured adipocytes 1.
NAD+, SAM, and fat-cell metabolism
NAD+, short for nicotinamide adenine dinucleotide, helps cells move energy through key reactions. SAM, short for S-adenosylmethionine, helps with methylation reactions. These pathways are biologically important, but changing them in a lab model does not prove that a person will lose weight safely.
Why a mechanism does not prove human weight loss
Many compounds look promising in cells or animals and then fail in people. Human trials are needed because appetite, hormones, liver and kidney handling, side effects, adherence, and long-term safety are much more complex than a cell dish or mouse model 7.
Does 5-Amino-1MQ really work for weight loss?
The honest answer: human weight-loss results are not established. Published evidence supports 5-Amino-1MQ as an investigational NNMT inhibitor in preclinical models, but that is not the same as showing safe, effective weight loss in patients 1.
What cell studies can and cannot show
Cell studies can show whether a compound hits a target, enters cells, and changes lab markers. In cultured adipocytes, 5-Amino-1MQ changed NNMT-linked metabolic pathways and lipogenesis markers 1. But cell studies cannot show real-world weight loss, side effects, drug interactions, or long-term safety in people.
What mouse studies found about fat mass and glucose metabolism
In diet-induced obese mice, researchers reported that 5-Amino-1MQ reduced body weight and white adipose tissue mass and improved measures related to glucose handling and insulin sensitivity 1. These are animal findings, so they should not be treated as proof of benefit for obesity, type 2 diabetes, or metabolic syndrome in humans.
What is missing: mature human efficacy and safety data
What is missing is the part patients need most: well-controlled human data showing dose, benefit, side effects, contraindications, and long-term outcomes. Until that exists, no one can responsibly promise predictable fat loss, better A1C, longer life, or lower cardiometabolic risk from 5-Amino-1MQ. Our guide to peptide side effects explains why unknown risks matter even when a compound sounds biologically plausible.
Is 5-Amino-1MQ legal in the United States?
5-Amino-1MQ is not FDA-approved as an obesity medication. Seeing it for sale online does not mean it has been cleared as a dietary supplement, prescription drug, or safe consumer product.
FDA explains that dietary supplements are regulated differently from drugs and are not approved by FDA for safety and effectiveness before marketing 8. FDA-approved drugs, by contrast, must go through an application process that reviews evidence for safety, effectiveness, labeling, and manufacturing quality 7.
Research chemical versus dietary supplement versus prescription drug
| Category | What it usually means | Patient concern |
|---|---|---|
| Research chemical | Sold for lab use, often labeled “not for human consumption” | Not a patient treatment pathway; safety and dosing for people may be unknown |
| Dietary supplement | A product taken by mouth that contains a dietary ingredient | Not FDA-approved to diagnose, treat, cure, or prevent disease 8 |
| FDA-approved prescription drug | Reviewed by FDA for a specific use, label, and manufacturing standards | Still requires clinician review because risks and contraindications vary 7 |
| Compounded prescription medication | Prepared for an individual patient by a licensed compounding pharmacy when legally appropriate | Not FDA-approved; should be used only with licensed clinician oversight 6 |
Why “third-party tested” does not mean FDA-approved
Third-party testing may check a sample for identity, potency, sterility, or contaminants. It does not replace FDA review for whether a product is safe and effective for a medical condition, and it does not create an approved patient label 6, 7. If you are evaluating a certificate of analysis, our article on peptide testing explains what testing can and cannot prove.
Why patients should avoid products labeled not for human consumption
If a seller says a compound is not for human consumption, take that language seriously. It means the product is not being presented as a medication or supplement for you to take, even if the marketing around it implies body-composition benefits.
How often do people take 5-Amino-1MQ?
There is no established patient dosing schedule for 5-Amino-1MQ. We do not recommend following online protocols because mature human efficacy and safety data are lacking.
The 2018 preclinical study used 5-Amino-1MQ in laboratory and mouse models, not as a patient dosing guide 1. Animal or cell methods should not be translated into a self-directed human plan.
| Compound | What dosing information exists | What it means for patients |
|---|---|---|
| 5-Amino-1MQ | Preclinical laboratory methods in cells and mice 1 | No established patient schedule; not a dosing recommendation |
| Semaglutide active ingredient | The FDA-approved Wegovy label starts at 0.25 mg once weekly for 4 weeks and titrates to maintenance dosing under the label 2 | A clinician decides whether semaglutide is appropriate; compounded semaglutide is not FDA-approved |
| Tirzepatide active ingredient | The FDA-approved Zepbound label starts at 2.5 mg once weekly for 4 weeks and uses stepwise titration under the label 3 | A clinician decides whether tirzepatide is appropriate; compounded tirzepatide is not FDA-approved |
What to ask a clinician if you are considering an investigational compound
- Is there human trial evidence for the outcome I want?
- What side effects and contraindications are known, and what is still unknown?
- Could this interact with my current medications or supplements?
- Could it affect pregnancy, fertility treatment, blood sugar, blood pressure, mood, liver function, or kidney function?
- Is there a better-studied option for my goal?
5-Amino-1MQ versus evidence-based weight-loss medications
Semaglutide and tirzepatide are not the same as 5-Amino-1MQ. They are incretin-based medications with large human trials; 5-Amino-1MQ is an investigational NNMT inhibitor with mainly preclinical evidence 1, 4, 5.
In STEP 1, adults with overweight or obesity receiving semaglutide 2.4 mg once weekly plus lifestyle intervention lost more weight than placebo over 68 weeks; individual results varied 4. In SURMOUNT-1, adults with obesity or overweight receiving tirzepatide once weekly plus lifestyle intervention lost more weight than placebo over 72 weeks; individual results varied 5. These trial results describe the active ingredients as studied, not compounded formulations.
| Option | Class and mechanism | Human weight-loss evidence | Common side effects and key risks | Chia availability |
|---|---|---|---|---|
| 5-Amino-1MQ | Investigational small-molecule NNMT inhibitor; often mislabeled as a peptide | Mostly cell and mouse data; mature human obesity data are not established 1 | Human side-effect profile, contraindications, interactions, and long-term risks are not well established | Not offered by Chia |
| Semaglutide; Wegovy and Ozempic are brand names; compounded semaglutide may be dispensed by state-licensed 503A pharmacies | GLP-1 receptor agonist that affects appetite, glucose signaling, and gastric emptying 2 | STEP 1 studied semaglutide 2.4 mg once weekly with lifestyle intervention for 68 weeks 4 | Nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder issues, pancreatitis warning, and contraindication with personal or family history of medullary thyroid carcinoma or MEN2 on the Wegovy label 2 | Chia offers compounded semaglutide injection; plans currently start at $249/mo |
| Tirzepatide; Zepbound and Mounjaro are brand names; compounded tirzepatide may be dispensed by state-licensed 503A pharmacies | Dual GIP/GLP-1 receptor agonist that affects appetite and glucose-related pathways 3 | SURMOUNT-1 studied once-weekly tirzepatide with lifestyle intervention for 72 weeks 5 | Nausea, diarrhea, vomiting, constipation, abdominal pain, gallbladder issues, pancreatitis warning, and contraindication with personal or family history of medullary thyroid carcinoma or MEN2 on the Zepbound label 3 | Chia offers compounded tirzepatide tablets or injections; plans currently start at $249/mo for tablets and $299/mo for injections |
Lifestyle support still matters with any obesity medication. In major semaglutide and tirzepatide obesity trials, medication was studied alongside lifestyle intervention, not as a stand-alone substitute for nutrition, movement, sleep, and follow-up care 4, 5.
3-min quiz
Considering medical weight-loss treatment?
Chia offers clinician-reviewed access to compounded semaglutide injection and compounded tirzepatide tablets or injections when clinically appropriate. A licensed US provider reviews your health history first, and a prescription is never guaranteed. Compounded drugs are not FDA-approved.
Weight-loss and metabolic treatment options at Chia
Chia does not offer 5-Amino-1MQ. If your goal is weight loss or metabolic health support, our providers can review whether a better-studied, clinician-guided option fits your health history.
At Chia, treatment starts online with a short health questionnaire. A licensed US provider reviews your history, medications, goals, and safety factors, then prescribes only when clinically appropriate. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door.
| Chia option | Forms Chia offers | Current starting price | How it may fit |
|---|---|---|---|
| Compounded semaglutide | Injection; microdosing plans available | Plans currently start at $249/mo | For patients whose provider determines semaglutide is clinically appropriate |
| Compounded tirzepatide | Tablets or injection; microdosing plans available | Plans currently start at $249/mo for tablets and $299/mo for injections | For patients whose provider determines tirzepatide is clinically appropriate and who want a tablet or injection option |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | Plans currently start at $309/mo | For patients discussing weight-loss treatment with metabolic energy-support goals |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | Plans currently start at $329/mo | For patients discussing weight-loss treatment with body-composition and muscle-support goals |
Chia also offers NAD+ therapy as injection or nasal spray and sermorelin as injection, nasal spray, or tablets. These are separate treatments with separate eligibility reviews; they are not substitutes for an obesity medication, and they are prescribed only when clinically appropriate.
Provider-guided dosing matters because GLP-1 and GIP/GLP-1 medications can cause gastrointestinal side effects and may not be appropriate for some people. FDA labels for semaglutide and tirzepatide include warnings about pancreatitis, gallbladder disease, kidney injury related to dehydration, and a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN2 2, 3.
What should you do if you already bought 5-Amino-1MQ?
If you already bought 5-Amino-1MQ, do not assume supplement-style packaging means it is safe to take. Save the bottle, box, ingredient list, seller page, lot number, and certificate of analysis if one was provided.
Before using it or combining it with other medications, talk with a licensed clinician or pharmacist. This is especially important if you take diabetes medication, blood pressure medication, stimulants, psychiatric medication, hormones, or any injectable weight-loss medication.
- Do not inject or swallow a product labeled “not for human consumption.”
- Do not mix it with semaglutide, tirzepatide, NAD+, sermorelin, or other compounds without clinician review.
- If you already used it and feel chest pain, severe vomiting, fainting, allergic symptoms, confusion, or severe abdominal pain, seek urgent care.
- If your goal is weight loss, ask about options with human evidence, safety labeling, and monitoring.
How does online treatment access work through Chia?
Chia’s online visit is built around clinician review, not self-service ordering. You complete a health questionnaire, a licensed US provider reviews it, and medication is prescribed only when clinically appropriate.
If prescribed, compounded medication is prepared by a US state-licensed 503A pharmacy and shipped to your door. Dosing is provider-guided and adjusted over time when needed, including microdosing plans for semaglutide or tirzepatide where clinically appropriate.
Patients can message their care team through the portal between visits. For people using AI agents to organize care, Chia is also reachable through DoctorMCP at mcp.chia.health when that access path is relevant to their workflow.
3-min quiz
Start with a licensed clinical review
If you are looking for evidence-based weight-loss care rather than 5-Amino-1MQ, you can start an online Chia visit. Your provider will review eligibility, contraindications, medication interactions, and safety risks before deciding whether treatment is appropriate. A prescription is not guaranteed, and compounded medications are not FDA-approved.
No. 5-Amino-1MQ is commonly marketed as a peptide, but it is a synthetic small molecule called 5-amino-1-methylquinolinium. It is studied as an NNMT inhibitor.
No. 5-Amino-1MQ is not FDA-approved as an obesity medication, diabetes medication, supplement ingredient, or anti-aging treatment.
Mature human evidence showing safe, effective weight loss is not established. Most published evidence discussed for 5-Amino-1MQ comes from cell and animal models.
This article does not provide legal advice about compounding 5-Amino-1MQ. Chia does not prescribe or sell 5-Amino-1MQ, and patients should not treat research-chemical listings as prescription care.
No. Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP/GLP-1 receptor agonist. 5-Amino-1MQ is an investigational NNMT inhibitor with a different mechanism and much less human weight-loss evidence.
No. Chia does not offer 5-Amino-1MQ. Chia offers clinician-reviewed care for listed treatments such as compounded semaglutide injection and compounded tirzepatide tablets or injections when clinically appropriate.
Possibly, depending on your health history and clinical eligibility. Chia’s licensed providers review your intake and prescribe only when appropriate. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and results for compounded formulations are not FDA-evaluated.
References
- 1.Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Scientific Reports. 2018.
- 2.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
- 3.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2025.
- 4.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- 6.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers. 2024.
- 7.U.S. Food and Drug Administration. Development and approval process: Drugs. 2024.
- 8.U.S. Food and Drug Administration. Questions and answers on dietary supplements. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
